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Purpose: The aim of this study was to assess visual and refractive outcomes of laser 
vision correction (LVC) to correct residual refraction after multifocal intraocular lens (IOL) 
implantation.
Patients and methods: In this retrospective study, 782 eyes that underwent LVC to correct 
unintended ametropia after multifocal IOL implantation were evaluated. Of all multifocal lenses 
implanted during primary procedure, 98.7% were refractive and 1.3% had a diffractive design. 
All eyes were treated with VISX STAR S4 IR excimer laser using a convectional ablation profile. 
Refractive outcomes, visual acuities, patient satisfaction, and quality of life were evaluated at 
the last available visit.
Results: The mean time between enhancement and last visit was 6.3±4.4 months. Manifest 
spherical equivalent changed from −0.02±0.83 D (−3.38 D to +2.25 D) pre-enhancement to 
0.00±0.34 D (−1.38 D to +1.25 D) post-enhancement. At the last follow-up, the percentage 
of eyes within 0.50 D and 1.00 D of emmetropia was 90.4% and 99.5%, respectively. Of all 
eyes, 74.9% achieved monocular uncorrected distance visual acuity 20/20 or better. The mean 
corrected distance visual acuity remained the same before (−0.04±0.06 logMAR [logarithm of 
the minimum angle of resolution]) and after LVC procedure (−0.04±0.07 logMAR; P=0.70). 
There was a slight improvement in visual phenomena (starburst, halo, glare, ghosting/double 
vision) following the enhancement. No sight-threatening complications related to LVC occurred 
in this study.
Conclusion: LVC in pseudophakic patients with multifocal IOL was safe, effective, and 
predictable in a large cohort of patients.
Keywords: excimer laser enhancements, pseudophakic patients, multifocal IOL
Introduction
Cataract surgery is one of the most commonly performed ophthalmic procedures 
in the world. In modern ophthalmology, phacoemulsification with intraocular lens 
(IOL) implantation is becoming more of a refractive procedure with patients having 
higher expectations and seeking spectacle independence. Despite advances in IOL 
formulas and surgical and biometric techniques, unintended postoperative ametropia 
cannot be always eliminated. Common causes of undesired refractive error include 
inaccuracies in preoperative measurements or biometric calculations,1–3 variations 
in lens formulas,4,5 incorrect selection of IOL power,6 manufacturing precision, or 
postoperative positional changes.1,6
Established surgical techniques to rectify refractive error after IOL implantation 
are excimer laser surgery,7–18 astigmatic keratectomy,19 IOL exchange,19–23 and an 
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implantation of a piggyback IOL.19–23 Laser in situ ker-
atomileusis (LASIK) or photorefractive keratectomy (PRK) 
were found to be the most accurate and safest surgical options 
for pseudophakic ametropia,19–23 with other techniques (IOL 
exchange or secondary IOL) being used mainly in the cases 
of higher ametropia or in eyes where excimer laser ablation 
is contraindicated.
In patients with multifocal IOLs, postoperative refractive 
error can possibly exacerbate problems inherent to these lens 
designs, such as loss of contrast sensitivity or photic phe-
nomena, resulting in higher postoperative dissatisfaction.24,25 
Some reports also suggest that surgical correction of refrac-
tive error in eyes with multifocal IOL might be technically 
more difficult.16,17 This is due to difficulties in estimating 
refractive error caused by increased depth of focus and split 
of light to several foci in multifocal designs,16,17 as well as 
problems associated with measuring refractive error by 
automated devices26 or estimation of higher-order aberration 
with Hartmann–Shack aberrometers if wavefront-guided 
(WFG) treatment is intended.27,28
To date, only a few reports have been published on 
clinical outcomes of LASIK/PRK in pseudophakic patients 
implanted with multifocal IOLs,11,13–17 with small numbers 
of patients involved. The aim of this study was to present 
predictability, safety, and efficacy of excimer laser correction 
for undesired ametropia in pseudophakic patients implanted 
with multifocal IOLs in a large cohort of patients.
Patients and methods
A retrospective data review was performed to identify patients 
who had excimer laser retreatment for residual ametropia fol-
lowing the primary cataract/refractive lens exchange with 
an implantation of a multifocal IOL between December 
2013 and June 2015. The study was deemed exempt from 
full review by the Committee of Human Research at the 
University of California, San Francisco, because it used only 
the retrospective, de-identified patient data. Written informed 
consent to undergo primary and enhancement procedure was 
obtained from all patients.
A total of 782 eyes of 576 patients were included in this 
study. Criteria for retreatment were that patients were unhappy 
with some aspect of their vision (either blurred distant and/
or near vision or visual symptoms) that was related to their 
residual refractive error and an in-clinic demonstration using 
trial frames improved their symptoms. If there was any doubt 
about eligibility for enhancement, patients underwent a con-
tact lens or spectacle trial for several days to demonstrate 
whether the gain in near/distance vision would warrant a 
surgical procedure. In addition, they had to have a stable 
manifest refraction of no more than a 0.50 D change in either 
sphere or cylinder, documented over a minimum of 3 months. 
Only patients with a follow-up of 1 month or more post-
enhancement were included in this study. Exclusion criteria 
for enhancement were active ophthalmic diseases, presence of 
posterior capsular opacification, abnormal corneal shape, con-
current medications, or medical conditions that could impair 
healing and a calculated residual stromal bed ,250 µm.
Ophthalmic examination prior to the initial procedure 
included manifest and cycloplegic refraction, uncorrected 
distance visual acuity (UDVA), corrected distance visual 
acuity (CDVA), uncorrected near visual acuity (UNVA), 
slitlamp evaluation, dilated fundoscopy, autorefraction and 
tonometry (Tonoref II; Nidek Co. Ltd., Gamagori, Japan), 
corneal topography (Pentacam; Oculus, Inc., Wetzlar, 
Germany), endothelial cell count (SP-2000P specular 
microscope; Topcon Europe BV, Newbury, UK), biometry 
(IOLMaster; Carl Zeiss Meditec AG, Jena, Germany), and 
retinal optical coherence tomography (Cirrus 4000 OCT; 
Carl Zeiss Meditec AG). Visual acuity was measured at 
distance using a Snellen visual acuity chart and close-up 
using a logarithmic near visual acuity chart (the Early Treat-
ment Diabetic Retinopathy Study) at 40 cm. Near visual 
acuity was recorded in Snellen distance equivalent (meters). 
Biometry (IOLMaster) was used for lens calculation and 
surgeon preference determined the choice of IOL formula. 
Generally, Haigis or Holladay II formulas were used in most 
cases, and other formulas (such as Hoffer-Q and SRK/T) were 
considered in eyes with extreme axial lengths. All eyes were 
targeted for emmetropia.
The same examinations as prior to initial procedure were 
carried out prior to enhancement, excluding cycloplegic 
refraction and biometry. All patients were advised to return 
for follow-up at 1 day, 4 days (surface ablation only), 1 week, 
1 month, and 3 months and thereafter as required. The data 
of the last available postoperative visit are presented in this 
study. Manifest refraction, UDVA, UNVA, CDVA, and 
slitlamp examinations were performed postoperatively.
All patients were asked to complete a questionnaire 
during their postoperative visits. It was self-administered by 
the patient using a password protected and secure computer 
terminal in an isolated area of the clinic. The questionnaire 
responses were stored in the secured Optical Express central 
database, which is compliant with ISO 27001 for information 
security management systems. The questionnaire was derived 
from the Joint LASIK Study Task Force.29 Patients were asked 
to rate their satisfaction with visual acuity as well as difficulty 
with night vision phenomena and various tasks that require 
close-up or distance vision (Figure 1). The last available 
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questionnaire prior to enhancement and the last available 
questionnaire post-enhancement were used for analysis.
Primary procedure surgical technique
All intraocular surgeries were performed under sub-Tenon’s 
anesthetic block with a mild sedation. A toric IOL was used 
in patients with preoperative corneal cylinder .1.50 D 
(94 eyes).
Most corneal incisions were made on the steepest 
corneal meridian to neutralize corneal astigmatism. After 
phacoemulsification, a foldable multifocal IOL was inserted 
into the capsular bag through a 2.75 mm corneal incision. 
Surgery in the second eye was usually performed 1 week 
later. Postoperatively, patients were instructed to instill one 
drop of levofloxacin 0.5% (Oftaquix) four times daily for 
2 weeks and one drop of dexamethasone 0.1% (Maxidex) 
four times daily for 2 weeks.
retreatment surgical technique
LASIK eyes had corneal flaps created by a femtosecond 
laser (iFS; Abbott Medical Optics Inc., Santa Ana, CA, 
USA). The diameter of the femtosecond flaps ranged from 
8.0 mm to 9.2 mm, and the programmed depth ranged from 
100 µm to 120 µm. Flaps were subsequently lifted and the 
programmed treatment was applied to exposed stroma. All 
surgical procedures were performed under topical anesthesia. 
Standard postoperative treatment was administered to all 
patients consisting of topical levofloxacin 0.5% and topical 
Figure 1 Questions from patient satisfaction questionnaire.
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prednisolone acetate 1% four times a day for 1 week, and 
preservative-free artificial tear drops.
In eyes having surface ablation, the eye was topically 
anesthetized and a 9 mm well was placed on the cornea and 
filled with 20% ethanol. Following a 30–40-second applica-
tion, the alcohol was drained with a surgical spear and the eye 
was irrigated with a balanced salt solution. The epithelium was 
removed with a blunt spatula, the programmed treatment was 
applied, and a bandage contact lens was placed on the eye and 
left in place until the cornea was re-epithelialized. Postoperative 
medication consisted of topical levofloxacin 0.5%, four times 
a day for 1 week, and 4 weeks of a tapering dose of topical 
fluorometholone ophthalmic solution 0.1% in the following 
sequence: four times a day for 1 week, three times a day for 1 
week, two times a day for 1 week, and once a day for 1 week.
Excimer laser enhancements were performed with a con-
ventional ablation profile using VISX STAR S4 IR excimer 
laser (Abbott Medical Optics Inc.). Treatment was based on 
patient’s manifest refraction, and nomogram adjustment was 
applied based on the previous experience with conventional 
ablations on primary laser vision correction (LVC) cases.
For myopic treatments, the optical zone (OZ) diameter 
was 6.5 mm; for myopic astigmatism, the major axis of 
the elliptical OZ was 6.5 mm with a minor axis as small as 
5.0 mm depending on the amount of myopia and astigmatism. 
The transition zone was 8 mm, unless there was ,1.0 D of 
myopia. Hyperopic treatments had 6.0 mm OZ and 9.0 mm 
transition zone. LASIK was the preferred enhancement 
procedure, which was performed on 91.2% of eyes. Where 
clinical parameters (such as corneal pachymetry and 
topography) did not allow creation of LASIK flap, PRK was 
performed (8.8% of eyes).
statistical analysis
Normality of data samples was evaluated by the Kolmogorov–
Smirnov test. When normality condition could be assumed, 
paired Student’s t-test was used to compare preoperative and 
postoperative data. When parametric analysis was not possible, 
Wilcoxon rank sum test was applied in place of paired t-test. 
To compare independent groups of patients, unpaired t-test 
or Mann–Whitney U-test were used, depending on the nor-
mality of data sample. Chi-square test was used to compare 
percentages. Correlation coefficients were calculated to find 
the association between questionnaire responses and clinical 
parameters. All the data were analyzed using Microsoft Office 
Excel 2007 program (Microsoft Corporation, Redmond, WA, 
USA) and STATISTICA (StatSoft Inc., Tulsa, OK, USA) on a 
personal computer. A P-value of 0.05 was considered statisti-
cally significant.
Results
A total of 782 eyes of 576 patients were analyzed in this study. 
The mean age at the time of enhancement was 57.4±7.2 years 
(range: 34–76 years). The mean time from IOL surgery to 
enhancement was 7.4±2.5 months. Of all patients, 266 (46.2%) 
were females, and 310 (53.8%) were males. Table 1 presents 
the lens designs implanted during primary cataract/refractive 
lens exchange procedure. A majority of eyes (98.7%) were 
implanted with IOLs with a segmental refractive design. The 
initial data (prior to intraocular procedure) and pre- and post-
enhancement data are summarized in Table 2.
Figure 2 shows the distribution of pre- and post- 
enhancement manifest spherical equivalent (MSE). Prior to 
laser enhancement, 41.2% of eyes were within 0.50 D and 
84.7% were within 1.00 D of MSE. Post-enhancement, the 
percentage of eyes within 0.50 D and 1.00 D of emmetropia 
was 90.4% and 99.5%, respectively. The reduction in 
the mean refractive sphere and cylinder was statistically 
significant (Table 2). A linear regression of attempted pre-
enhancement vs achieved post-enhancement MSE correction 
(Figure 3) had a slope of 1.06 and intercept of 0.002.
Figure 4 depicts the cumulative monocular UDVA 
prior to primary procedure, prior to enhancement, and post- 
enhancement. Prior to enhancement, 2.3% of patients had 
Table 1 Multifocal lens types implanted during primary cataract/refractive lens exchange procedure
IOL model (manufacturer) IOL technology Number of eyes (%)
lentis Mplus ls-313 MF30 (Oculentis gmbh) refractive, nonrotational symmetric 401 (51.3)
lentis Mplus toric lU-313 MF30T (Oculentis gmbh) refractive, nonrotational symmetric (toric) 65 (8.3)
lentis MplusX ls-313 MF30 (Oculentis gmbh) refractive, nonrotational symmetric 213 (27.2)
lentis MplusX toric lU-313 MF30T (Oculentis gmbh) refractive, nonrotational symmetric (toric) 29 (3.7)
lentis Mplus ls-313 MF15 (Oculentis gmbh) refractive, nonrotational symmetric 20 (2.6)
lentis Mplus ls-313 MF20 (Oculentis gmbh) refractive, nonrotational symmetric 14 (1.8)
sBl-3 (lenstec, inc.) refractive, nonrotational symmetric 30 (3.8)
FineVision (PhysiOl s.a.) Diffractive trifocal 9 (1.2)
Tecnis ZMB00 (abbott Medical Optics inc.) Diffractive 1 (0.1)
Abbreviation: iOl, intraocular lens.
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UDVA 20/16 or better and 7.8% 20/20 or better. These were 
mostly eyes with low amount of hyperopia or mixed astigma-
tism, where the small amount of refractive error affected the 
multifocal performance of the IOL. The percentage of eyes 
achieving 20/16 or 20/20 or better UDVA post-enhancement 
was 39.4% and 74.9%, respectively. Binocularly, 44.1% of 
patients had UDVA 20/20 or better prior to enhancement and 
92.0% post-enhancement. Figure 5 shows the cumulative 
UNVA. The percentage of patients achieving monocular 
UNVA 20/40 (J5) or better was 61.3% prior to enhance-
ment and 76.6% post-enhancement. Binocularly, 75.8% 
and 86.6% of patients achieved 20/40 UNVA pre- and post-
enhancement, respectively.
Figure 6 shows the comparison of pre-enhancement 
CDVA to post-enhancement CDVA. The mean change in 
CDVA was not statistically significant (Table 2). The loss 
of two lines of CDVA at the last available follow-up was 
recorded in 1.4% of eyes (eleven eyes). The reasons for 
CDVA loss were as follows: nine eyes – ocular surface 
dryness/superficial punctate keratitis, one eye – age-related 
macular changes that were not present at the time of enhance-
ment, one eye – traumatic eye injury not related to the 
enhancement resulting in prolonged corneal edema.
Table 3 shows the pre- and post-enhancement clinical 
outcomes stratified by the type of pre-enhancement refractive 
error. Prior to enhancement, 32.5% of eyes had myopia or 
myopic astigmatism, 49.2% of eyes were hyperopic or had 
hyperopic astigmatism and 18.3% had mixed astigmatism. 
All the three categories had significant reduction in sphere, 
cylinder, and MSE (Table 3). The percentage of patients 
Table 2 refractive and visual outcomes (n=782 eyes)
Prior to cataract/refractive 
lens exchange
Prior to 
enhancement
Last visit P-value pre- to 
post-enhancement
sphere (D), mean ± sD (range) +1.08±3.05 (−18.75 to +9.0) +0.42±0.83 
(−3.00 to +2.50)
+0.15±0.35 
(−1.25 to +1.50)
,0.01
Cylinder (D), mean ± sD (range) −0.84±0.86 (−7.00 to 0.00) −0.87±0.55 
(−4.00 to 0.00)
−0.29±0.33 
(−1.50 to 0.00)
,0.01
Mse (D), mean ± sD (range) +0.66±3.09 (−19.38 to +8.50) −0.02±0.83 
(−3.38 to +2.25)
0.00±0.34 
(−1.38 to +1.25)
0.52
UDVa (logMar), mean ± sD (range) 0.56±0.43 (−0.08 to 1.60) 0.20±0.15 
(−0.08 to 1.00)
0.00±0.10 
(−0.18 to 0.70)
,0.01
CDVa (logMar), mean ± sD (range) −0.04±0.08 (−0.18 to 0.70) −0.04±0.06 
(−0.18 to 0.30)
−0.04±0.07 
(−0.18 to 0.70)
0.70
Follow-up (months) Primary to enhancement 7.4±2.5 enhancement to last visit 6.3±4.4
Abbreviations: CDVa, corrected distance visual acuity; D, diopter; logMar, logarithm of the minimum angle of resolution; Mse, manifest spherical equivalent; UDVa, 
uncorrected distance visual acuity.
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Figure 2 Comparison of pre- and post-enhancement Mse.
Abbreviations: D, diopter; Mse, manifest spherical equivalent.
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hyperopic sphere: PRK, +0.85±0.49 D; LASIK, +0.82±0.47 D; 
P=0.68). Eyes in the PRK group had higher pre-enhancement 
cylinder (PRK, −1.03±0.58 D; LASIK, −0.86±0.55 D; P=0.02) 
and worse pre-enhancement CDVA (PRK, −0.02±0.08 
logMAR [logarithm of the minimum angle of resolution]; 
LASIK, −0.04±0.06 logMAR; P=0.02).
There was no statistically significant difference in post-
operative sphere (PRK, +0.18±0.32 D; LASIK, +0.14±0.35 D; 
P=0.49), cylinder (PRK, −0.30±0.36 D; LASIK, 
−0.29±0.32 D; P=0.81), UDVA (PRK, 0.0±0.10 logMAR; 
LASIK, 0.0±0.10 logMAR; P=0.99), or CDVA (PRK, 
−0.03±0.07 logMAR; LASIK, −0.04±0.07 logMAR; 
P=0.53) between the two groups. When evaluating difficul-
ties with post-enhancement dry eye symptoms (measured on 
scale 1= no difficulty to 7= severe difficulty; Figure 1), the 
mean score for PRK was 2.2±1.4 and for LASIK 2.2±1.5 
(P=0.89).
There was also no statistically significant difference in 
post-enhancement visual symptoms between the two groups 
(mean score: starburst: PRK 2.2±1.4, LASIK 2.1±1.5, 
P=0.64; glare: PRK 1.9±1.3, LASIK 2.3±1.6; P=0.17, 
halo: PRK 1.8±1.3, LASIK 2.2±1.6, P=0.19; ghosting: PRK 
1.8±1.4, LASIK 1.9±1.5, P=0.45).
Toric multifocal lenses
Ninety-four eyes in the study had a toric multifocal IOL 
implanted during their primary IOL procedure. The 
mean refractive cylinder in this subgroup of patients 
was −1.25±0.74 D prior to enhancement, and reduced 
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Figure 3 Predictability – scattergram of attempted pre-enhancement Mse 
correction vs achieved post-enhancement Mse correction.
Notes: area between two dotted lines represents Mse within 0.50 D, and area 
between dashed lines represents Mse within 1.00 D of emmetropia. solid red line 
is the linear regression.
Abbreviations: D, diopter; Mse, manifest spherical equivalent.
?????
?????
????
????
????
????
??? ???????????????
???? ????
?????
???? ????
?????
????? ?????
????? ?????
????? ???????????
?????
?????
??????????????????????????????????
???
???
????
?????
???
??????????????? ??????????????? ????????????????
???????????? ?????????????????????????????????????????????????
Figure 4 Cumulative monocular UDVa.
Abbreviation: UDVa, uncorrected distance visual acuity.
achieving post-enhancement UDVA 20/20 or better was 
71.1% in the myopic group, 76.4% in the hyperopic group, 
and 77.4% in the mixed astigmatism group.
lasiK vs PrK enhancement
PRK was performed on 69 eyes and LASIK on 713 
eyes. There was no statistically significant difference in 
pre-enhancement myopic or hyperopic sphere (myopic 
sphere: PRK, −0.72±0.41 D; LASIK, −0.73±0.49 D; P=0.85; 
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Figure 5 Cumulative monocular UnVa.
Abbreviation: UnVa, uncorrected near visual acuity.
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Figure 6 Change in CDVa prior to enhancement to post-enhancement.
Abbreviation: CDVa, corrected distance visual acuity.
to −0.23±0.30 D (P,0.01). There was no statistically 
significant difference in the residual post-enhancement 
refractive cylinder in eyes that had a toric IOL and non-toric 
IOL (mean post-LVC cylinder in patients with non-toric 
IOL: −0.30±0.33 D, P=0.06).
Complications
Out of all eyes that had LASIK enhancements (n=713), two 
eyes (0.3%) developed peripheral epithelial ingrowth that 
stabilized and did not affect visual acuity or refraction. Mild 
diffused lamellar keratitis was observed in 33 eyes (4.6%), 
and except for a temporary increase in topical steroid dosing, 
all resolved without additional intervention. One eye had 
more severe diffused lamellar keratitis (grade 3) and was 
successfully treated with increased topical steroids. There 
was one case of flap striae affecting the patient’s CDVA/
quality of vision and a surgical intervention was required. 
Following a successful flap lift, the patient’s CDVA returned 
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to the preoperative level. In one eye without inflammation 
or pain, a presumed sterile corneal infiltrate was observed 
on the first postoperative day. The patient was maintained 
on his/her broad-spectrum topical antibiotic, and the topical 
steroid was increased in frequency. The infiltrate resolved 
within the first 5 postoperative days.
In the group of eyes with surface ablation (n=69), two 
eyes (2.9%) developed mild haze, which cleared within the 
first 6 postoperative months. There was one case of delayed 
epithelial healing that required management with therapeutic 
contact lenses for 1 month and, finally, resolved without any 
consequence. One patient suffered from recurrent erosion 
syndrome following the bilateral PRK, which was also 
managed with therapeutic contact lenses and intense ocular 
surface lubrication.
Patient-reported outcomes and 
satisfaction
Of all patients, 81.3% (n=468) completed both pre- and post-
enhancement questionnaires. The mean patient satisfaction 
(measured on the scale 1–5; Figure 1) changed from 2.3±1.1 
before enhancement to 1.9±1.0 (P,0.01) post-enhancement. 
The percentage of patients being dissatisfied/very dissatisfied 
with their vision decreased from 17.0% prior to enhancement 
to 9.5% post-enhancement (P,0.01).
Figure 7 shows the proportion of patients experiencing 
severe difficulty with night vision phenomena and severe 
difficulty with tasks requiring distance or near vision. There 
was a slight improvement in all symptoms from pre- to 
post-enhancement level, although most of the percentage 
differences were not statistically significant (Figure 7). 
The mean change in visual phenomena scores from pre- to 
post-LVC enhancement (all measured on a scale between 
1= no difficulty to 7= severe difficulty) indicated a slight 
but statistically significant improvement in all symptoms. 
The mean score for starburst improved from 2.4±1.7 before 
LVC enhancement to 2.1±1.5 (P=0.01) post-enhancement, 
and the change in other optical side effects was as follows: 
glare: 2.5±1.6 to 2.2±1.6, P=0.03; halo: 2.4±1.7 to 2.1±1.6, 
P=0.03; ghosting/double vision: 2.2±1.7 to 1.9±1.5, P,0.01. 
Overall, there was a slight improvement in visual phenomena 
symptoms post-enhancement. The mean score for dry eye 
symptoms changed from 2.0±1.4 prior to enhancement to 
2.2±1.5 post-enhancement (P=0.06).
Out of all clinical parameters, the final satisfaction with 
visual acuity was most strongly correlated with postop-
erative monocular UDVA (r=0.19, P,0.01). Post-LVC 
enhancement satisfaction was also strongly correlated with T
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Figure 7 Patient satisfaction questionnaire outcomes.
Notes: Severe difficulty with starburst, glare, halo, ghosting/double vision – percentage of patients who scored 6 or 7 on scale 1= no difficulty to 7= severe difficulty. Severe 
difficulty with driving at night, close-up activities, and outdoor activities – percentage of patients who scored “a lot of difficulty” or “never try to do these activities because 
of my vision”. Chi-square test was used to compare percentages.
all the other questionnaire items. For example, the correla-
tion between satisfaction and difficulty with glare post-
enhancement was r=0.55 (P,0.01), and the same applied 
to all the other ocular side effects (starburst, glare, ghosting/
double vision). It was the final post-LVC enhancement glare 
(or any other visual phenomena) that affected patient satis-
faction more than the change between pre- and post-LVC 
enhancement glare, which was still significantly correlated 
with patient satisfaction, but the correlation was weaker 
(r=0.26, P,0.01). Despite the pre-enhancement demonstra-
tion of visual symptoms in trial frames or with contact lens/
spectacle trial, some patients may have believed that the 
enhancement would further improve their quality-of-vision 
issues. It is likely that many of these persistent symptoms 
were inherent to the multifocal IOL.
The satisfaction was also affected by the difficulty per-
forming tasks such as night driving (r=0.54, P,0.01), close-up 
activities (r=0.53, P,0.01), and difficulty with outdoor 
activities (r=0.44, P,0.01). There was a strong relationship 
between patient satisfaction and the difficulty with dry eye 
symptoms at the last follow-up (r=0.50, P,0.01).
Discussion
Despite the use of accurate lens calculation formulas, 
optimization of A-constants, use of customized toric 
lenses, and improvements in micro-incision intraocular 
surgery, undesired postoperative refractive error is still an 
issue.19–23 In a recent retrospective review of .17,000 cataract 
procedures,30 emmetropia (defined as spherical equivalent 
within ±0.50 D with ,1.00 D of astigmatism) was finally 
achieved only in 55% of eyes. In our previous series of 
9,366 eyes implanted with a nonrotational symmetric lens,31 
which is the IOL primarily used in the majority of eyes in 
this study, 91.8% were within ±1.00 D of MSE at 3 months 
postoperatively. Although this refractive predictability 
was good, it also indicates that a not-insignificant fraction 
of these patients would require additional procedures to 
achieve emmetropia. Variables routinely measured before 
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cataract surgery (such as age, refraction, axial length, and 
intraocular pressure) cannot accurately predict the need for 
LVC enhancement.32
In the current study, 90.4% of eyes were within 0.50 D 
and 99.5% within 1.00 D of emmetropia following the laser 
enhancement. Only 7.8% of patients had UDVA 20/20 or 
better prior to enhancement, and this number increased to 
74.9% post-enhancement. The mean CDVA was almost the 
same before (−0.04±0.06 logMAR) and after enhancement 
(−0.04±0.07 logMAR). The symptoms of photic phenomena 
slightly reduced following the enhancement (Figure 7), but 
they did not completely disappear, which is expected with 
the use of multifocal lens designs.
There are several reasons why results of laser enhance-
ments in pseudophakic patients could be different from pri-
mary laser patients. Patients with cataract are typically 2 to 
3 decades older, and older age can be associated with lower 
predictability and efficacy of excimer ablation,33,34 as well as 
higher susceptibility to tear-film deficiency.35 The pseudopha-
kic patients typically have one or two corneal incisions, 
as well as additional incisions to correct astigmatism. It 
is possible that these incisions could be slightly distorted 
during suction required for the creation of LASIK flap and 
affect postoperative outcomes.12,23 Despite these potential 
concerns, excellent outcomes have been reported with the 
use of excimer laser ablation in pseudophakic patients,7–18 
and it remains the preferred surgical option for unintended 
ametropia.19–23 Predictability was confirmed in many stud-
ies in patients with monofocal IOL;7–10,12,16 however, to our 
knowledge, only a few studies have been previously pub-
lished on the use of excimer laser surgery in patients with a 
multifocal lens.11,13–17
In the first report, Leccisotti11 presented outcomes of 
18 eyes that had PRK for residual refractive error after the 
implantation of Array SA40N refractive IOL (AMO, Inc., 
Santa Ana, CA, USA). Postoperative spherical equivalent 
was slightly hyperopic (+0.33 D), with the mean postopera-
tive UDVA of 0.8 (=0.1 logMAR). Fifteen eyes (83%) were 
within 0.50 D of emmetropia. The study concluded that PRK 
significantly improved visual acuity, but it had limited effect 
on halos associated with Array lens and some patients eventu-
ally required an exchange to a monofocal lens.
Alfonso et al14 presented outcomes of 53 eyes that under-
went LASIK for residual ametropia after the implantation 
of AcrySof ReSTOR (Alcon, Inc., Hünenberg, Switzerland) 
apodized diffractive IOL, using conventional ablation profile 
and femtosecond laser for flap creation. Excellent outcomes 
were achieved in terms of predictability: all eyes were within 
±1.00 D and 96.2% were within ±0.50 D of the desired 
refraction. This is slightly superior to our outcomes, but a 
much lower range of refractions was treated in this study 
(pre-enhancement MSE: −2.00 D to +1.00 D, compared 
to the MSE of the current study, ranging between −3.38 D 
and +2.25 D). Six months after LASIK, the mean UDVA 
was 0.83±0.20 (≈0.08 logMAR).
In 2008, Jendritza et al13 published outcomes of 27 pseu-
dophakic eyes treated with WFG LASIK. Twenty-four eyes 
had a diffractive multifocal IOL (Tecnis; Abbott Medical 
Optics Inc., or ReSTOR), and four eyes had a refractive IOL 
(ReZoom; Abbott Medical Optics Inc.). The conclusion was 
that WFG LASIK could successfully treat residual ametropia 
in patients with multifocal lens implant, but it did not improve 
higher-order aberrations. The authors advised against the 
use of WFG ablation in patients with refractive IOLs, as the 
measurements with wavefront sensors may not be reliable. 
WFG LASIK in eyes with diffractive IOLs did not affect 
multifocality of the lens, and the patients retained about the 
same corrected near and distance visual acuity following 
the excimer laser ablation. On the other hand, in the group 
of patients with a refractive IOL, there was one-line loss of 
distance corrected and two lines loss of near corrected visual 
acuity. However, these conclusions were based only on four 
eyes included in this subcategory. The majority of patients 
in our study (98.7%) had an IOL with refractive design, and 
there was no loss in the mean CDVA.
Muftuoglu et al15 retrospectively studied 85 eyes with 
apodized diffractive IOL, which were enhanced for residual 
myopia, hyperopia, or mixed astigmatism. Of the whole 
cohort, 15% of eyes had WFG ablation. Pre-enhancement 
spherical equivalent ranged between −2.58 D and +1.63 D 
and postoperatively, 96% and 99% of eyes were within 
0.50 D and 1.00 D of targeted refraction. Postoperative mean 
UDVA was 0.05±0.08 logMAR, and there was no difference 
in achieved UDVA between eyes with preoperative myopia, 
hyperopia, and mixed astigmatism. This is comparable 
to our outcomes, where UDVA was very close to 20/20 
(0.0 logMAR) in all the three subcategories (Table 3).
Piñero et al16 compared the outcomes of LASIK for 
pseudophakic ametropia in eyes with monofocal IOL and 
multifocal IOL with 50 eyes in each group. Of all eyes, 84% 
were within 0.50 D of emmetropia in the monofocal group 
and 70% in the multifocal group, and this difference was not 
statistically significant. Postoperative UDVA was similar in 
both the groups (0.15±0.18 logMAR in the multifocal group, 
0.14±0.11 logMAR in the monofocal group). When examin-
ing eyes with multifocal IOL, no difference in postoperative 
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outcomes was found between eyes with diffractive and 
refractive lenses. The authors further divided the eyes with 
multifocal IOLs into those that had hyperopic and those with 
myopic pre-enhancement refractive error, and they concluded 
that eyes with hyperopic error had less predictable outcomes. 
Eyes with preoperative hyperopia had tendency for undercor-
rection, and there was a higher variability in postoperative 
MSE (+0.32±0.72 D), whereas eyes with preoperative myo-
pia were slightly overcorrected, but the standard deviation 
of postoperative MSE was lower (+0.28±0.45 D). This was 
attributed to the difficulties in estimating refractive error in 
patients with multifocal IOL caused by the presence of several 
foci, which can result in artifacts in subjective refraction due 
to several refractive options providing similar visual qual-
ity. They recommended the use of the midpoint refraction 
of the clear vision interval provided by the depth of field of 
the IOL to avoid postoperative problems of predictability. 
In contrast, Albarrán-Diego et al17 describe difficulty in treat-
ing pseudophakic patients with multifocal IOL with myopic 
residual refraction. However, this study is only a case report 
of three eyes with unexpected hyperopic surprise.
The findings of our study did not confirm those of Piñero 
et al.16 Eyes with preoperative myopia or hyperopia had both 
predictable outcomes with the mean postoperative spherical 
equivalent close to emmetropia, with very similar standard 
deviation (myopic eyes: +0.04±0.36 D, n=254; hyperopic 
eyes: −0.03±0.33, n=385). The percentage of eyes within 
0.50 D of targeted refraction was actually slightly higher in 
patients with preoperative hyperopia (91.7%) than those with 
myopic error (87.5%; Table 3), although this difference was 
not statistically significant. One possible explanation could 
be careful pre-enhancement counseling and examination. 
Patients with slight hyperopic error are mostly affected by 
inability to see well close-up, but they often have very good 
distance visual acuity. Thus, contact lens or spectacle trial 
is often necessary to ensure that the patient will benefit from 
enhancement and that postoperative overall visual acuity will 
not be affected. The refraction determined from this trial is 
then used in preoperative planning.
In this study, LASIK was the preferred choice for the 
enhancement of pseudophakic ametropia, which was per-
formed in 91.3% of eyes. Although the group of patients with 
surface ablation was much smaller, there was no statistically 
significant difference in any of the postoperative clinical 
parameters between the two techniques. LASIK is a popu-
lar choice due to its fast and relatively pain-free recovery; 
however, there could be an increased risk of dry eye symptoms 
with the creation of the corneal flap, especially in a group of 
older patients who are more prone to tear-film abnormalities. 
Despite this concern, we did not find a statistically significant 
difference in postoperative dry eye symptoms between the 
two techniques. Both enhancement methods might potentially 
have increased complication rates related to older age. Surface 
ablation might require longer re-epithelialization period due 
to the age-related decrease in the healing response,36,37 which 
was observed only in one case in this study. On the other hand, 
the creation of LASIK flap temporarily increases intraocular 
pressure, which could result in complications associated with 
posterior segment of the eye,38 such as retinal detachment, 
macular hemorrhage, damage to optic nerve, and visual field 
defect. We did not see any vitreoretinal complications related 
to LASIK in our cohort of 724 eyes. However, our patients 
were younger (57.4±7.2 years) than a typical population of 
patients undergoing cataract surgery. In addition, patients 
with posterior segment pathology were excluded during 
preoperative screening as this would be a contraindication 
to multifocal IOL implantation.
Conclusion
Our study had several limitations. Although there were a large 
number of patients involved, the study was retrospective and 
there was a variation in the time between the enhancement 
and the last postoperative visit. Thus, we could not calculate 
the stability of outcomes over the period of time. Despite this, 
findings of this study confirmed that excimer ablation can 
be safely and successfully utilized in eyes with multifocal 
lens and undesired pseudophakic ametropia. Due to the age 
of this population, patients should be carefully counseled 
for possible increase in dry eye symptoms, and some of the 
undesired optical side effects might remain despite the suc-
cessful correction of refractive error.
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